Z. Lehner

55P0110, a Novel Synthetic Compound Developed from a Plant Derived Backbone Structure, Shows Promising Anti-Hyperglycaemic Activity in Mice

A. Luger, K. Frobel, I. Adorjan, 2015, PloS one.

Evidence that the multiflorine‐derived substituted quinazolidine 55P0251 augments insulin secretion and lowers blood glucose via antagonism at α2‐adrenoceptors in mice

M. Scheinin, A. Kautzky-Willer, I. Adorjan, 2019, Diabetes, obesity & metabolism.

Dissection of mechanisms that account for imidazoline-induced lowering of blood glucose in mice.

A. Luger, I. Rustenbeck, C. Fürnsinn, 2014, European journal of pharmacology.

Preclinical characterization of 55P0251, a novel compound that amplifies glucose‐stimulated insulin secretion and counteracts hyperglycaemia in rodents

A. Luger, I. Adorjan, C. Fürnsinn, 2017, Diabetes, obesity & metabolism.

Mechanisms of antihyperglycaemic action of efaroxan in mice: time for reappraisal of α2A-adrenergic antagonism in the treatment of type 2 diabetes?

A. Luger, K. Frobel, I. Rustenbeck, 2012, Diabetologia.

Participatory Game Design for the INTERACCT Serious Game for Health

Helmut Hlavacs, Fares Kayali, Manuel Sprung, 2015, JCSG.

A Participatory Game Design Approach for Children After Cancer Treatment

Helmut Hlavacs, Fares Kayali, Manuel Sprung, 2014, ACE '14 Workshops.

Lipophilicity as a determinant of thiazolidinedione action in vitro: findings from BLX-1002, a novel compound without affinity to PPARs.

A. Luger, C. Fürnsinn, K. Staniek, 2011, American journal of physiology. Cell physiology.